Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Dasatinib

FDA-approved product (tablet, oral), marketed as Dasatinib, Phyrago, Sprycel.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Dasatinib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Acute lymphoblastic leukemia
  • B-cell acute lymphoblastic leukemia
  • Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
  • Cancer
  • Childhood acute lymphoblastic leukemia
  • Childhood cancer
  • Chronic myelogenous leukemia
  • Lymphoblastic lymphoma
  • Lymphoid leukemia
  • Neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Bcr-abl tyrosine kinase inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA54.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli50.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae24.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis49.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Dasatinib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.4 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.9 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.7 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.0 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Dasatinib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

    NCT02465060 · start 2015-08-17

    Registered record
    Registry ID
    NCT02465060
    Conditions
    Advanced Lymphoma; Advanced Malignant Solid Neoplasm; Bladder Carcinoma; Breast Carcinoma; Cervical Carcinoma; Colon Carcinoma; Colorectal Carcinoma; Endometrial Carcinoma; Esophageal Carcinoma; Exocrine Pancreas Carcinoma; Gastric Carcinoma; Glioma; Head and Neck Carcinoma; Hematopoietic and Lymphoid Cell Neoplasm; Kidney Carcinoma; Liver Carcinoma; Lung Carcinoma; Lymphoma; Malignant Uterine Corpus Neoplasm; Malignant Uterine Neoplasm; Melanoma; Multiple Myeloma; Ovarian Carcinoma; Prostate Carcinoma; Rectal Carcinoma; Recurrent Bladder Carcinoma; Recurrent Breast Carcinoma; Recurrent Cervical Carcinoma; Recurrent Colon Carcinoma; Recurrent Colorectal Carcinoma; Recurrent Esophageal Carcinoma; Recurrent Gastric Carcinoma; Recurrent Glioma; Recurrent Head and Neck Carcinoma; Recurrent Liver Carcinoma; Recurrent Lung Carcinoma; Recurrent Lymphoma; Recurrent Malignant Solid Neoplasm; Recurrent Malignant Uterine Corpus Neoplasm; Recurrent Melanoma; Recurrent Multiple Myeloma; Recurrent O
    Interventions
    Adavosertib; Afatinib; Afatinib Dimaleate; Binimetinib; Biopsy Procedure; Biospecimen Collection; Capivasertib; Computed Tomography; Copanlisib; Copanlisib Hydrochloride; Crizotinib; Cytology Specimen Collection Procedure; Dabrafenib; Dabrafenib Mesylate; Dasatinib; Defactinib; Defactinib Hydrochloride; Echocardiography Test; Erdafitinib; Fexagratinib; Ipatasertib; Laboratory Biomarker Analysis; Larotrectinib; Larotrectinib Sulfate; Magnetic Resonance Imaging; Multigated Acquisition Scan; Nivolumab; Osimertinib; Palbociclib; Pertuzumab; PI3K-beta Inhibitor GSK2636771; Radiologic Examination; Radionuclide Imaging; Relatlimab; Sapanisertib; Sunitinib Malate; Taselisib; Trametinib; Trastuzumab; Trastuzumab Emtansine; Ulixertinib; Vismodegib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2015-08-17
    Completion
    2026-12-31
    Enrolment
    6,452

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Lymphoma; Advanced Malignant Solid Neoplasm; Bladder Carcinoma; Breast Carcinoma +38 more
    InterventionAdavosertib; Afatinib; Afatinib Dimaleate; Binimetinib +38 more
    PhasePhase 2
    Registry statusActive not recruiting

  • Continuing Treatment for Subjects Who Have Participated on a Prior Protocol Investigating Dasatinib

    NCT02297139 · start 2015-07-31

    Registered record
    Registry ID
    NCT02297139
    Conditions
    Multiple Indications Cancer
    Interventions
    Dasatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2015-07-31
    Completion
    2022-05-15
    Enrolment
    17

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Indications Cancer
    InterventionDasatinib
    PhasePhase 2
    Registry statusCompleted

  • Multicenter, PhaseⅣ, Open Label Trial of Nilotinib in Adult Patients Diagnosed Philadelphia Chromosome Positive(Ph+) Chronic Myeloid Leukemia in CP/AP Intolerant to Dasatinib

    NCT02389920 · start 2015-04

    Registered record
    Registry ID
    NCT02389920
    Conditions
    Leukemia, Chronic Myeloid
    Interventions
    Nilotinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2015-04
    Completion
    2018-12
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLeukemia, Chronic Myeloid
    InterventionNilotinib
    PhasePhase 4
    Registry statusUnknown

  • Treatment-free Remission Accomplished With Dasatinib in Patients With CML

    NCT02268370 · start 2014-10

    Registered record
    Registry ID
    NCT02268370
    Conditions
    Chronic Myeloid Leukemia
    Interventions
    Dasatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2014-10
    Completion
    2021-10
    Enrolment
    131

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Myeloid Leukemia
    InterventionDasatinib
    PhasePhase 2
    Registry statusUnknown

  • Treating Patients With Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) With Dasatinib

    NCT02348957 · start 2014-10

    Registered record
    Registry ID
    NCT02348957
    Conditions
    Myeloid Leukemia, Chronic, Chronic-Phase
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2014-10
    Completion
    2019-05
    Enrolment
    223

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMyeloid Leukemia, Chronic, Chronic-Phase
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer

    NCT02059265 · start 2014-02-14

    Registered record
    Registry ID
    NCT02059265
    Conditions
    Endometrial Clear Cell Adenocarcinoma; Ovarian Clear Cell Cystadenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Recurrent Uterine Corpus Cancer
    Interventions
    Dasatinib; Laboratory Biomarker Analysis
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2014-02-14
    Completion
    2023-06-26
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEndometrial Clear Cell Adenocarcinoma; Ovarian Clear Cell Cystadenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma +2 more
    InterventionDasatinib; Laboratory Biomarker Analysis
    PhasePhase 2
    Registry statusTerminated

  • Open-Label Study Evaluating Dasatinib Therapy Discontinuation in Patients With Chronic Phase Chronic Myeloid Leukemia With Stable Complete Molecular Response

    NCT01850004 · start 2014-01-22

    Registered record
    Registry ID
    NCT01850004
    Conditions
    Chronic Phase Chronic Myeloid Leukemia
    Interventions
    Dasatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2014-01-22
    Completion
    2021-10-08
    Enrolment
    84

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Phase Chronic Myeloid Leukemia
    InterventionDasatinib
    PhasePhase 2
    Registry statusCompleted

  • Selecting Patient-Specific Biologically Targeted Therapy for Pediatric Patients With Refractory Or Recurrent Brain Tumors

    NCT02015728 · start 2013-12

    Registered record
    Registry ID
    NCT02015728
    Conditions
    Recurrent Childhood Brain Tumor
    Interventions
    Tumor biology testing; Temozolomide; Etoposide; Sorafenib; Everolimus; Erlotinib; Dasatinib
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2013-12
    Completion
    2017-12
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecurrent Childhood Brain Tumor
    InterventionTumor biology testing; Temozolomide; Etoposide; Sorafenib +3 more
    PhaseNot applicable
    Registry statusUnknown

  • Multimodal Molecular Targeted Therapy to Treat Relapsed or Refractory High-risk Neuroblastoma

    NCT01467986 · start 2013-08

    Registered record
    Registry ID
    NCT01467986
    Conditions
    Neuroblastoma Recurrent
    Interventions
    Dasatinib; Rapamycin; Irinotecan; Temozolomide; Irinotecan; Temozolomide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2013-08
    Completion
    2020-09-30
    Enrolment
    130

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeuroblastoma Recurrent
    InterventionDasatinib; Rapamycin; Irinotecan; Temozolomide +2 more
    PhasePhase 2
    Registry statusCompleted

  • TKI Therapy Based on Molecular Monitoring in Allogeneic-HSCT Recipients With Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

    NCT01883219 · start 2013-06

    Registered record
    Registry ID
    NCT01883219
    Conditions
    Philadelphia Chromosome Positive Acute Lymphocytic Leukemia; Stem Cell Transplantation; Minimal Residual Disease
    Interventions
    TKIs
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2013-06
    Completion
    2017-11
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPhiladelphia Chromosome Positive Acute Lymphocytic Leukemia; Stem Cell Transplantation; Minimal Residual Disease
    InterventionTKIs
    PhasePhase 2
    Registry statusUnknown

  • Dasatinib for Patients Achieving Complete Molecular Response for Cure D-NewS Trial

    NCT01887561 · start 2012-11

    Registered record
    Registry ID
    NCT01887561
    Conditions
    Myelogenous Leukemia, Chronic, Chronic Phase
    Interventions
    dasatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2012-11
    Completion
    Not recorded
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMyelogenous Leukemia, Chronic, Chronic Phase
    Interventiondasatinib
    PhasePhase 2
    Registry statusUnknown

  • A Randomized Phase II Trial Comparing Therapy Based on Tumor Molecular Profiling Versus Conventional Therapy in Patients With Refractory Cancer

    NCT01771458 · start 2012-10

    Registered record
    Registry ID
    NCT01771458
    Conditions
    Reccurent/Metastatic Solid Tumor Disease
    Interventions
    Targeted therapy based on molecular profiling : Imatinib; Tumor biopsy; Standard Chemotherapy; Targeted therapy based on molecular profiling : Everolimus; Targeted therapy based on molecular profiling : Vemurafenib; Targeted therapy based on molecular profiling : Sorafenib; Targeted therapy based on molecular profiling : Erlotinib; Targeted therapy based on molecular profiling : Lapatinib + Trastuzumab; Targeted therapy based on molecular profiling : Dasatinib; Targeted therapy based on molecular profiling : Tamoxifen (or letrozole if contra-indication); Targeted therapy based on molecular profiling : Abiraterone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2012-10
    Completion
    2016-12
    Enrolment
    742

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionReccurent/Metastatic Solid Tumor Disease
    InterventionTargeted therapy based on molecular profiling : Imatinib; Tumor biopsy; Standard Chemotherapy; Targeted therapy based on molecular profiling : Everolimus +7 more
    PhasePhase 2
    Registry statusCompleted

  • An Open-Label, Phase I/II Study of Two Different Schedules of Dasatinib (Sprycel) and Decitabine (Dacogen) Used in Combination for Patients With Accelerated or Blastic Phase Chronic Myelogenous Leukemia (Protocol CA180357)

    NCT01498445 · start 2012-06-12

    Registered record
    Registry ID
    NCT01498445
    Conditions
    Leukemia
    Interventions
    Dasatinib; Decitabine; Decitabine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Terminated
    Start
    2012-06-12
    Completion
    2019-09-24
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLeukemia
    InterventionDasatinib; Decitabine; Decitabine
    PhasePhase 1 / Phase 2
    Registry statusTerminated

  • Study of Dasatinib and All-Trans Retinoic Acid for Relapsed/Refractory and/or Elderly Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome

    NCT00892190 · start 2011-04

    Registered record
    Registry ID
    NCT00892190
    Conditions
    Acute Myelogenous Leukemia; Myelodysplastic Syndrome
    Interventions
    dasatinib (SPRYCEL); all trans retinoic acid (VESANOID)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-04
    Completion
    2016-02
    Enrolment
    9

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Myelogenous Leukemia; Myelodysplastic Syndrome
    Interventiondasatinib (SPRYCEL); all trans retinoic acid (VESANOID)
    PhasePhase 1
    Registry statusCompleted

  • Treatment With Dasatinib in Patients With Acral Lentiginous, Mucosal, or Chronic Sun-damaged Melanoma

    NCT01092728 · start 2011-03

    Registered record
    Registry ID
    NCT01092728
    Conditions
    Melanoma
    Interventions
    Dasatinib; Surgical Resection
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2011-03
    Completion
    2014-08
    Enrolment
    19

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMelanoma
    InterventionDasatinib; Surgical Resection
    PhasePhase 2
    Registry statusTerminated